Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005921 · ClinicalTrials.gov registry record · NA
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
A NA study of HIV Infections and Candidiasis, Esophageal, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00005921: Completed NA study of HIV Infections and Candidiasis, Esophageal, sponsored by Merck Sharp & Dohme.
NCT00005921 is a NA study of HIV Infections and Candidiasis, Esophageal that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 18 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005921, a NA study of HIV Infections and Candidiasis, Esophageal, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.
Conditions Studied
Interventions
- DRUG L-743,872
Study Locations (1)
New Jersey
- Gary Calandra - Rahway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Phase | NA |
What the finished NCT00005921 record still lists
NCT00005921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which L-743,872 is the first listed.
NCT00005921 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00005921 about?
NCT00005921 is a clinical study titled "A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis". The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.
What is the current status of trial NCT00005921?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants.
What conditions does trial NCT00005921 study?
This clinical trial studies the following conditions: HIV Infections, Candidiasis, Esophageal.
What interventions are being tested in trial NCT00005921?
The interventions under investigation include: L-743,872 (DRUG).
Who is sponsoring clinical trial NCT00005921?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005921 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005921's enrollment target sits among peer trials
18 504th of 542 higher than 31 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes